Use of Geriatric Assessment Tools in Selecting Therapies in Women Aged ≥70 Years With Hormone Receptor–Positive Early-Stage Breast Cancer: Preliminary Experience With a Quality Improvement Initiative
Jean L. Wright(University of North Carolina at Chapel Hill), Vered Stearns(Johns Hopkins University), Karen L. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Colette Magnant, Nancy L. Schoenborn(Johns Hopkins University), Yao Yao Pollock(University of Michigan), Arti Parekh(University of Maryland, Baltimore)
International Journal of Radiation Oncology*Biology*Physics
January 29, 2017
Cited by 20
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Elastography of breast lesions: initial clinical results.
|Radiology|1997|934
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850